A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by up to 40% The treatment pairs standard hormone therapy with a targeted drug that blocks cancer growth, offering fresh hope for men with advanced or treatment-resistant prostate cancer. Researchers say this dual-therapy approach extends life and improves quality.